The FDA announced today that it granted emergency use authorization (EUA) for an at-home COVID-19 diagnostic test from Laboratory Corporation of America (NYSE:LH). LabCorp received EUA for its COVID-19 RT-PCR test last month, saying at the time that it would rapidly expand its testing capabilities with the expectation of more than 20,000 tests performed per […]
Wearable sensor developer MC10 said this week it inked a collaborative deal with LabCorp that included an equity investment of an undisclosed amount. Through the collaborative deal, Lexington, Mass.-based MC10 said that LabCorp will use MC10s proprietary sensor technology for its Covance Drug Development business in clinical trials and research studies, with the possibility of adapting […]
Diagnostics company LabCorp (NYSE:LH) said today that it has closed its $1.2 billion acquisition of contract research organization Chiltern International. Chiltern is slated to fold into the company’s Covance drug development business, which conducts clinical trials for drugmakers. Get the full story at our sister site, Drug Delivery Business News.
(Reuters) – Diagnostics company Laboratory Corp of America Holdings said on Monday it would buy privately owned contract research organization Chiltern International Ltd for nearly $1.2 billion in cash to expand its oncology offerings. The CRO industry is undergoing a wave of consolidation as pharmaceutical companies strive to cut costs, reduce clinical trial times and expand their […]
Emulate, Inc. and LabCorp‘s (NYSE:LH) Covance Drug Development biz inked a deal to collaborate for an organ-on-a-chip preclinical drug evaluation and testing service. Emulate’s organ-on-a-chip tech is designed to be a predictive model of the human body’s response to diseases and medications. The companies plan to combine the organ modeling tech with Covance’s expertise of drug […]
(Reuters) – Laboratory Corporation of America Holdings said it would buy Sequenom Inc, a maker of non-invasive prenatal tests for reproductive health, for about $371 million, including debt. The $2.40 per share cash offer, which has a total equity value of $302 million, represents a 182% premium to Sequenom’s Tuesday close. Sequenom’s shares rose 177% […]